KKR Genetic Disorder L.P. 13D and 13G filings for BridgeBio Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-14 5:52 pm Sale | 2025-05-12 | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 13,260,971 7.000% | -6,000,000 (-31.15%) | Filing |
| 2025-03-07 6:15 pm Sale | 2025-03-05 | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 19,260,971 10.100% | -6,000,000 (-23.75%) | Filing |
| 2024-09-17 6:41 pm Sale | 2024-09-13 | 13D | BRIDGEBIO PHARMA INC BBIO | KKR Genetic Disorder L.P. | 25,260,971 13.400% | -5,800,000 (-18.67%) | Filing |